Progyny logo
Progyny PGNY
$ 26.55 -0.62%

Quarterly report 2025-Q3
added 11-07-2025

report update icon

Progyny Financial Ratios 2011-2025 | PGNY

Annual Financial Ratios Progyny

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

177.5 260.9 115.8 68.2 78.2 -69.4 - - - - - - - -

P/S

6.3 13.0 4.5 9.0 10.5 2.6 - - - - - - - -

EPS

0.1 0.1 0.3 0.7 0.5 -0.4 0.0 -2.4 - - - - - -

EV (Enterprise Value)

1.89 B 3.62 B 3.56 B 4.5 B 3.65 B 551 M 30.2 M 24.3 M - - - - - -

EBITDA per Share

0.22 0.17 0.27 0.38 0.12 0.57 - - - - - - - -

EV/EBITDA

132.9 388.6 43.6 - - - - - - - -

PEG

- 0.13 0.17 - - - - - - - -

P/B

4.4 6.3 9.3 17.8 21.8 5.2 - - - - - - - -

P/CF

10.4 18.6 43.7 172.3 100.4 -132.5 - - - - - - - -

ROE %

2.50 2.43 8.05 26.12 27.83 -7.50 - - - - - - - -

ROA %

1.73 1.78 5.59 18.37 18.30 -5.70 - - - - - - - -

ROCE %

3.74 2.49 6.19 12.84 5.00 8.47 - - - - - - - -

Current Ratio

3.3 3.7 3.3 3.4 2.9 3.7 - - - - - - - -

DSO

291.8 325.8 86.9 76.6 64.9 74.8 - - - - - - - -

DPO

171.3 201.1 50.3 49.3 41.8 38.4 - - - - - - - -

Operating Cycle

291.8 325.8 86.9 76.6 65.0 74.8 - - - - - - - -

Cash Conversion Cycle

120.6 124.8 36.6 27.4 23.2 36.4 - - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios Progyny

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

0.16 0.2 0.18 - 0.12 0.18 0.18 - 0.17 0.16 0.19 - 0.14 0.1 0.05 0.17 0.19 0.21 0.17 0.45 0.06 -0.01 0.04 -0.07 -1.1 - 0.01 -0.3 -0.2 -0.22 0.73 - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

- - 0.3 - - - 0.2 - - - 0.17 - 0.13 0.1 - - 0.11 0.13 0.14 0.01 0.07 - 0.05 0.02 0.62 0.66 0.24 -0.14 0.14 -0.06 -0.32 - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

11.42 11.34 11.63 8.97 12.05 12.74 12.32 10.44 14.25 14.98 14.60 8.41 14.39 18.08 24.42 30.85 48.27 43.66 33.87 27.83 0.57 -9.50 -7.53 -7.50 -2.05 6.33 5.90 3.69 2.09 0.90 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

7.63 7.47 7.58 3.94 6.13 6.74 6.58 7.11 9.70 10.10 9.09 4.98 9.19 10.40 16.40 20.35 31.52 28.44 22.02 18.30 -0.02 -7.37 -5.94 -5.70 -6.46 -3.75 -4.76 -6.44 -2.75 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

16.61 15.63 15.44 10.64 14.17 14.83 13.53 10.30 13.55 13.26 12.87 6.07 5.99 6.79 9.65 16.06 16.83 15.68 9.34 5.00 5.31 5.10 7.80 8.47 8.21 6.14 4.42 1.70 0.96 0.34 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

3.4 3.1 2.8 3.3 2.9 2.9 - 3.7 3.4 3.2 2.9 3.3 3.1 - 3.1 3.4 3.0 2.9 2.7 2.9 2.9 2.9 2.9 4.2 4.2 4.2 4.2 1.4 1.4 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DSO

76.3 78.3 75.3 - 91.5 - - - 86.7 94.4 97.7 - 57.3 46.4 88.1 96.5 103.0 91.3 71.8 68.8 69.8 106.9 69.1 65.9 70.2 76.5 68.0 72.9 38.3 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DPO

50.0 51.4 44.3 - 56.6 - - - 54.8 57.5 58.2 - 29.8 25.6 47.9 52.0 53.6 51.6 49.3 49.9 50.9 75.4 44.5 33.2 36.2 39.6 42.9 59.8 31.2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

76.3 78.3 75.3 - 91.5 - - - 86.7 94.4 97.7 - 57.3 46.4 88.1 96.5 103.0 91.3 71.8 68.8 69.8 106.9 69.1 65.9 70.2 76.5 68.0 72.9 38.3 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash Conversion Cycle

26.3 26.9 31.1 - 34.8 - - - 31.9 36.9 39.5 - 27.5 20.8 40.3 44.5 49.4 39.7 22.5 19.0 18.9 31.4 24.6 32.8 34.0 36.9 25.2 13.1 7.0 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Progyny, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Health information services industry

Issuer Price % 24h Market Cap Country
Cerner Corporation Cerner Corporation
CERN
- - $ 27.9 B usaUSA
Computer Programs and Systems Computer Programs and Systems
CPSI
- 4.4 % $ 133 M usaUSA
Covetrus Covetrus
CVET
- - $ 2.94 B usaUSA
Accolade Accolade
ACCD
- 0.29 % $ 206 M usaUSA
Castlight Health, Inc. Castlight Health, Inc.
CSLT
- -7.28 % $ 227 M usaUSA
HMS Holdings Corp. HMS Holdings Corp.
HMSY
- - $ 3.29 B usaUSA
Inovalon Holdings, Inc. Inovalon Holdings, Inc.
INOV
- - $ 6.37 B usaUSA
OptimizeRx Corporation OptimizeRx Corporation
OPRX
$ 13.18 -1.38 % $ 226 M usaUSA
Premier Premier
PINC
$ 28.26 - $ 2.33 B usaUSA
Change Healthcare Change Healthcare
CHNG
- - $ 9.03 B usaUSA
Schrödinger Schrödinger
SDGR
$ 18.49 2.44 % $ 1.34 B usaUSA
Evolent Health Evolent Health
EVH
$ 4.12 -0.24 % $ 386 M usaUSA
Health Catalyst Health Catalyst
HCAT
$ 2.37 -3.86 % $ 143 M usaUSA
HealthStream HealthStream
HSTM
$ 24.32 0.62 % $ 739 M usaUSA
iCAD iCAD
ICAD
- - $ 102 M usaUSA
10x Genomics 10x Genomics
TXG
$ 15.62 1.0 % $ 1.83 B usaUSA
Akerna Corp. Akerna Corp.
KERN
- - $ 161 M usaUSA
HealthEquity HealthEquity
HQY
$ 96.14 -0.68 % $ 8.23 B usaUSA
American Well Corporation American Well Corporation
AMWL
$ 4.73 2.38 % $ 70.9 M usaUSA
Allscripts Healthcare Solutions Allscripts Healthcare Solutions
MDRX
- -10.39 % $ 886 M usaUSA
MTBC MTBC
MTBC
- -0.58 % $ 51.7 M usaUSA
GoodRx Holdings GoodRx Holdings
GDRX
$ 2.73 -3.37 % $ 1.05 B usaUSA
Omnicell Omnicell
OMCL
$ 43.23 -1.44 % $ 1.99 B usaUSA
1Life Healthcare 1Life Healthcare
ONEM
- - $ 3.37 B usaUSA
Zhongchao Zhongchao
ZCMD
$ 0.58 -3.18 % $ 3.02 M chinaChina
Phreesia Phreesia
PHR
$ 16.69 2.71 % $ 911 M usaUSA
So-Young International So-Young International
SY
$ 2.92 -5.66 % $ 232 M chinaChina
Signify Health Signify Health
SGFY
- -0.02 % $ 7.21 B usaUSA
R1 RCM R1 RCM
RCM
- - $ 3.81 B usaUSA
NantHealth NantHealth
NH
- -46.64 % $ 10.4 M usaUSA
NextGen Healthcare NextGen Healthcare
NXGN
- - $ 1.6 B usaUSA
Veeva Systems Veeva Systems
VEEV
$ 218.94 -1.91 % $ 35.1 B usaUSA
Streamline Health Solutions Streamline Health Solutions
STRM
- - $ 21.4 M usaUSA
Teladoc Health Teladoc Health
TDOC
$ 7.37 -2.51 % $ 1.26 B usaUSA
Tabula Rasa HealthCare Tabula Rasa HealthCare
TRHC
- - $ 255 M usaUSA
SCWorx Corp. SCWorx Corp.
WORX
$ 0.2 -0.75 % $ 292 K usaUSA